SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Trichopoulos D) "

Sökning: WFRF:(Trichopoulos D)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Tidskriftsartikel (refereegranskat)
  •  
2.
  • Tidskriftsartikel (refereegranskat)
  •  
3.
  • Tidskriftsartikel (refereegranskat)
  •  
4.
  • Tidskriftsartikel (refereegranskat)
  •  
5.
  • Tidskriftsartikel (refereegranskat)
  •  
6.
  •  
7.
  •  
8.
  • Gapstur, S. M., et al. (författare)
  • Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies
  • 2015
  • Ingår i: The Lancet. - : Elsevier. - 1474-547X. ; 385:9980, s. 1835-1842
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years of use (RR 1.43, 95% CI 1.31-1.56; p<0.0001). Combining current-or-recent use (any duration, but stopped <5 years before diagnosis) resulted in an RR of 1.37 (95% CI 1.29-1.46; p<0.0001); this risk was similar in European and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but differed across the four main tumour types (heterogeneity p<0.0001), being definitely increased only for the two most common types, serous (RR 1.53, 95% CI 1.40-1.66; p<0.0001) and endometrioid (1.42, 1.20-1.67; p<0.0001). Risk declined the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was still an excess of serous or endometrioid tumours (RR 1.25, 95% CI 1.07-1.46, p=0.005). Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.
  •  
9.
  • Jacobs, Kevin B, et al. (författare)
  • Detectable clonal mosaicism and its relationship to aging and cancer.
  • 2012
  • Ingår i: Nature Genetics. - New York : Nature Publishing Group. - 1061-4036 .- 1546-1718. ; 44:6, s. 651-658
  • Tidskriftsartikel (refereegranskat)abstract
    • In an analysis of 31,717 cancer cases and 26,136 cancer-free controls from 13 genome-wide association studies, we observed large chromosomal abnormalities in a subset of clones in DNA obtained from blood or buccal samples. We observed mosaic abnormalities, either aneuploidy or copy-neutral loss of heterozygosity, of >2 Mb in size in autosomes of 517 individuals (0.89%), with abnormal cell proportions of between 7% and 95%. In cancer-free individuals, frequency increased with age, from 0.23% under 50 years to 1.91% between 75 and 79 years (P = 4.8 × 10(-8)). Mosaic abnormalities were more frequent in individuals with solid tumors (0.97% versus 0.74% in cancer-free individuals; odds ratio (OR) = 1.25; P = 0.016), with stronger association with cases who had DNA collected before diagnosis or treatment (OR = 1.45; P = 0.0005). Detectable mosaicism was also more common in individuals for whom DNA was collected at least 1 year before diagnosis with leukemia compared to cancer-free individuals (OR = 35.4; P = 3.8 × 10(-11)). These findings underscore the time-dependent nature of somatic events in the etiology of cancer and potentially other late-onset diseases.
  •  
10.
  • Beral, V., et al. (författare)
  • Ovarian Cancer and Body Size: Individual Participant Meta-Analysis Including 25,157 Women with Ovarian Cancer from 47 Epidemiological Studies
  • 2012
  • Ingår i: PLoS Medicine. - : Public Library of Science. - 1549-1676 .- 1549-1277. ; 9:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Only about half the studies that have collected information on the relevance of women's height and body mass index to their risk of developing ovarian cancer have published their results, and findings are inconsistent. Here, we bring together the worldwide evidence, published and unpublished, and describe these relationships. Methods and Findings: Individual data on 25,157 women with ovarian cancer and 81,311 women without ovarian cancer from 47 epidemiological studies were collected, checked, and analysed centrally. Adjusted relative risks of ovarian cancer were calculated, by height and by body mass index. Ovarian cancer risk increased significantly with height and with body mass index, except in studies using hospital controls. For other study designs, the relative risk of ovarian cancer per 5 cm increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09; p<0.001); this relationship did not vary significantly by women's age, year of birth, education, age at menarche, parity, menopausal status, smoking, alcohol consumption, having had a hysterectomy, having first degree relatives with ovarian or breast cancer, use of oral contraceptives, or use of menopausal hormone therapy. For body mass index, there was significant heterogeneity (p<0.001) in the findings between ever-users and never-users of menopausal hormone therapy, but not by the 11 other factors listed above. The relative risk for ovarian cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI, 1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p = 0.02) in ever-users of hormone therapy. Conclusions: Ovarian cancer is associated with height and, among never-users of hormone therapy, with body mass index. In high-income countries, both height and body mass index have been increasing in birth cohorts now developing the disease. If all other relevant factors had remained constant, then these increases in height and weight would be associated with a 3% increase in ovarian cancer incidence per decade.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (322)
konferensbidrag (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (305)
övrigt vetenskapligt (19)
Författare/redaktör
Trichopoulos, D (321)
Riboli, E. (168)
Trichopoulou, A (158)
Trichopoulos, Dimitr ... (147)
Tjonneland, A (146)
Overvad, K (145)
visa fler...
Boeing, H. (140)
Tumino, R. (137)
Lagiou, P (135)
Weiderpass, E (134)
Riboli, Elio (132)
Palli, D (124)
Kaaks, R. (121)
Adami, HO (113)
Khaw, Kay-Tee (112)
Boeing, Heiner (109)
Overvad, Kim (108)
Khaw, KT (107)
Trichopoulou, Antoni ... (106)
Vineis, P (106)
Bueno-de-Mesquita, H ... (104)
Tumino, Rosario (103)
Panico, S (102)
Bueno-de-Mesquita, H ... (100)
Kaaks, Rudolf (88)
Tjonneland, Anne (88)
Panico, Salvatore (88)
Palli, Domenico (87)
Clavel-Chapelon, F. (86)
Weiderpass, Elisabet ... (83)
Travis, Ruth C (82)
Vineis, Paolo (82)
Sánchez, Maria-José (79)
Clavel-Chapelon, Fra ... (73)
Peeters, Petra H (72)
Boutron-Ruault, Mari ... (71)
Wareham, N (71)
Lagiou, Pagona (68)
Lund, E. (67)
Ardanaz, E. (67)
Peeters, PH (67)
Boutron-Ruault, MC (66)
Travis, RC (63)
Peeters, Petra H M (63)
Sanchez, MJ (63)
Tjønneland, Anne (61)
Barricarte, A (58)
Olsen, A (57)
Romieu, I (57)
Ferrari, P. (56)
visa färre...
Lärosäte
Karolinska Institutet (166)
Umeå universitet (149)
Lunds universitet (104)
Uppsala universitet (41)
Göteborgs universitet (15)
Linköpings universitet (2)
visa fler...
Högskolan Dalarna (2)
visa färre...
Språk
Engelska (324)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (183)
Naturvetenskap (2)
Lantbruksvetenskap (2)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy